Drug Profile
Cirrhosis gene therapy - Bioenvision
Latest Information Update: 07 Feb 2017
Price :
$50
*
At a glance
- Originator Bioenvision
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver cirrhosis
Most Recent Events
- 06 Feb 2017 Discontinued - Phase-I for Cirrhosis in USA (Parenteral)
- 30 Jun 2006 Suspended - Phase-I for Cirrhosis in USA (Parenteral)
- 11 Aug 2003 Phase-I clinical trials in Cirrhosis in USA (Parenteral)